Denali Therapeutics Inc. announced that it has successfully closed a synthetic royalty funding agreement with Royalty Pharma, securing $200 million in gross proceeds. This significant funding comes shortly after the U.S. Food and Drug Administration (FDA) granted accelerated approval for tividenofusp alfa on March 24, 2026. The agreement is expected to enhance Denali's financial position and support the continued development of its pipeline. The funding will provide the company with the necessary resources to advance its clinical programs and potentially accelerate the commercialization of its therapies. This strategic move reflects Denali's commitment to addressing unmet medical needs in neurodegenerative diseases and positions the company for future growth. The successful closing of this agreement is a positive indicator of investor confidence in Denali's innovative approach and the potential market impact of its therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.